REG-Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
Alvotech reported H1 2026 adjusted revenue of $211.9 million, down 30.8% year-over-year, while adjusted EBITDA fell to $46.9 million due to manufacturing improvement impacts. The company strengthened its balance sheet with approximately $165 million in gross proceeds from an offering and a new $75 million term loan, and resubmitted US BLAs for AVT05, AVT06, and AVT03 with FDA decisions expected in Q4 2026.
Key figures
- Revenue
- 211900000
- Guidance
- 2026 total revenue $650-$700 million; adjusted EBITDA $180-$220 million
- Revenue Yoy
- -30.8%
- Cash balance
- 142800000
- Gross margin
- 54%
- Adjusted ebitda
- 46900000
- Offering proceeds
- 165000000
- Term loan facility
- 75000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.